Barclays Raises AbbVie (ABBV) Price Target to $325
Key Points
- Barclays maintained its Overweight rating on AbbVie Inc. on October 21, 2026, and raised its price target to $325.00 from $300.00.
- Barclays's $325 price target implies 12.43% upside from AbbVie Inc.'s ($ABBV) current $289.08 share price.
- AbbVie shares recently traded around $289.08, sitting below their 52-week high of $291.40 ahead of an October 30 earnings release.
- The biopharmaceutical firm posted trailing twelve-month revenue of $64.39 billion alongside earnings of $3.54 per share.
Get AbbVie text alerts
We text you when insiders, Congress, analysts or big funds move on $ABBV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
On October 21, 2026, Barclays maintained its Overweight rating on AbbVie Inc. (NYSE: ABBV) while lifting its price target from $300.00 to $325.00. The research note reflects the firm's forward-looking view on the drug maker's portfolio of immunology and oncology treatments.
ABBV
AbbVie Inc.
Barclays vs. the S&P 500
Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.
Barclays' Call on AbbVie
In its note on October 21, 2026, Barclays kept its Overweight rating on the stock and moved its target up to $325.00 from $300.00. The move adds to a busy stretch of Wall Street updates for the company leading up to its next financial report.
Other Institutional Activity in AbbVie
Large investors have been tuning their stakes in the pharmaceutical firm recently. Sumitomo Mitsui DS Asset Management Company trimmed its holdings by 32,919 shares, ending with 291,632 shares worth about $76.29 million. Meanwhile, AlphaStar Capital Management grew its position by 2,299 shares, finishing with 19,380 shares valued at roughly $5.07 million.
AbbVie Inc. Stock Up 1.3%
AbbVie shares recently traded around $291.40 at their 52-week peak, sitting at $289.08 as of October 21, 2026. That puts the stock up about 2.1% from its event-day close of $283.00. The share price stays well above its 200-day moving average of $233.95.
$ABBV price target
AbbVie Inc. daily closes and this analyst's $325 target. Not advice.
Recent Earnings
AbbVie reported trailing twelve-month revenue of $64.39 billion and earnings of $3.54 per share. The company operates with a net profit margin of 9.8% and yearly revenue growth of 10.2%. Investors are watching for the next earnings release scheduled for October 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
The company distributes an annual dividend of $6.92 per share, translating to a dividend yield of 2.45%. Its dividend payout ratio stands at 190.4%.
Insider Buying and Selling at AbbVie Inc.
Company insiders completed several transactions earlier in the year. General Counsel Perry C. Siatis sold 22,381 shares at $230.00 on February 25, 2026, for a total value of $5.15 million, followed by a sale of 18,668 shares valued at $4.38 million on March 2, 2026. Officer David Ryan Purdue sold 5,230 shares at $233.56 on March 4, 2026, yielding about $1.22 million. Later, on August 14, 2026, officer Nicholas Donoghoe sold 32,710 shares at $250.00 for a total of $8.18 million.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock through October. On October 8, 2026, JP Morgan maintained an Overweight rating and raised its target from $285.00 to $300.00. UBS maintained a Neutral rating on October 9, 2026, and lifted its target from $260.00 to $275.00. Guggenheim reiterated a Buy rating with a $288.00 target on October 9, 2026, while RBC Capital reiterated its Outperform rating with a $280.00 target on October 13, 2026. Overall, the stock carries a consensus buy rating and a mean price target of $282.61 across 28 analyst opinions.
About AbbVie
AbbVie Inc. is a research-focused biopharmaceutical company headquartered in North Chicago, Illinois. The firm discovers, develops, and markets medicines across immunology, oncology, and other therapeutic areas worldwide. Key products include Skyrizi for autoimmune conditions, Rinvoq for inflammatory disorders, and cancer therapies like Imbruvica, Venclexta, Elahere, and Epkinly.
Bottom Line
Barclays' revised target arrives just days ahead of the company's scheduled October 30 earnings report. Observers will track that upcoming update to see if revenue growth and drug sales keep pace with expectations.
Related Filing Alerts
Source: Barclays's rating change on $ABBV (Oct 21, 2026). Written by software, not financial advice. How we make alerts